Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update
Rigel (Nasdaq: RIGL) will report fourth quarter and full year 2025 financial results after market close on Tuesday, March 3, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rigel (Nasdaq: RIGL) will report fourth quarter and full year 2025 financial results after market close on Tuesday, March 3, 2026. A live conference call and webcast will follow at 4:30 p.m. ET to review results and provide a business update.
Investors can join by phone or via the Investor Relations webcast at www.rigel.com; the webcast will be archived for 90 days.
Details
News Market Reaction – RIGL
On Feb 24, the day this news came out, RIGL closed 0.73% above the previous close.
Data tracked by StockTitan Argus for the Feb 24 session.
Key Figures
- Earnings release date
- March 3, 2026
- Scheduled Q4 and full-year 2025 financial results
- Conference call time ET
- 4:30 p.m. Eastern Time
- Time of earnings call following results release
- Conference call time PT
- 1:30 p.m. Pacific Time
- Local time for company headquarters region
- Domestic dial-in
- 877-407-3088
- US phone access for live conference call
- International dial-in
- 201-389-0927
- International phone access for live conference call
- Webcast replay period
- 90 days
- Archived webcast availability on Rigel website
- Company founding year
- 1996
- Rigel founding date mentioned in company description
Historical Context
-
New director with extensive biotech and pharma commercial experience joined board.
-
First patient enrolled in Phase 1b/2 AML trial combining REZLIDHIA with other agents.
-
Preliminary Q4 and 2025 revenues plus 2026 revenue and income outlook provided.
-
Stock options and RSUs granted to new non-executive employees under inducement plan.
-
CEO presented company overview at J.P. Morgan Healthcare Conference webcast.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
hematologic disorders medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's website at www.rigel.com. The webcast will be archived and available for replay for 90 days after the call via the Rigel website.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in
Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David Rosen
Argot Partners
Phone: 646.461.6387
Email: david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-fourth-quarter-and-full-year-2025-financial-results-and-business-update-302695322.html
SOURCE Rigel Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.